Propanc Biopharma Inc 2026年季度报告

FORM 10-Q (Mark One) ☒QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-42806 PROPANC BIOPHARMA, INC.(Exact name of registrant as specified in its charter) Delaware33-0662986(State or other jurisdiction of(I.R.S. Employer incorporation or organization)Identification No.) 302, 6 Butler StreetCamberwell, VIC, 3124 Australia(Address of principal executive offices) (Zip Code) +61-03-9882-0780(Registrant’s telephone number, including area code) n/a(Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Actduring the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to suchfiling requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant wasrequired to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”and “emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filerSmaller reporting companyEmerging growth company Large accelerated filerNon-accelerated filer If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of May 14, 2026, there were 56,959,280 shares of the registrant’s common stock, $0.001 par value per share, issued and outstanding. PROPANC BIOPHARMA INC. Table of Contents PagePART I - FINANCIAL INFORMATION Item 1.Financial StatementsF-1Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations3Item 3.Quantitative and Qualitative Disclosures About Market Risk8Item 4.Controls and Procedures8 PART II - OTHER INFORMATION Item 1.Legal Proceedings9Item 1A.Risk Factors9Item 2.Unregistered Sales of Equity Securities and Use of Proceeds9Item 3.Defaults Upon Senior Securities9Item 4.Mine Safety Disclosures10Item 5.Other Information10Item 6.Exhibits10Signatures112 PART I — FINANCIAL INFORMATION Item 1. Financial Statements. The following unaudited interim condensed consolidated financial statements of Propanc Biopharma, Inc. are included in this Quarterly Reporton Form 10-Q: INDEX TO FINANCIAL STATEMENTS PageCondensed Consolidated Balance Sheets at March 31, 2026 (unaudited) and June 30, 2025F-2Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and nine months ended March 31,2026 and 2025 (unaudited)F-3Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for each of the three and nine months in the periodsended March 31, 2026 and 2025 (unaudited)F-4Condensed Consolidated Statements of Cash Flows for the nine months ended March 31, 2026 and 2025 (unaudited)F-5Notes to the Condensed Consolidated Financial Statements (unaudited)F-6F-1 Deferred offering costs-291,773Prepaid expenses - long-term portion6,057,42210,925,835Security deposit - related party2,0651,971Operating lease right-of-use assets, net - related party46,58459,413Property and equipment, net4,221- Accounts payable$973,692$1,249,596Accrued expenses and other payables942,3761,486,550Accrued interest123,181190,795Loans payable-65,280Loans payable - related parties, net of discount465,282415,329Notes payable, net of discount-543,312Convertible notes, net of discounts and including put premiums55,000537,921Operating lease liability - related party, current portion23,32417,664Warrant liability104,313-Embedded conversion option liabilities50,273403,892Employee benefit liability738,187667,901 PROPANC BIOPHARMA, INC. AND SUBSIDIARYCONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT) FOR THE THREEAND NINE MONTHS ENDED MARCH 31, 2026 AND 2025(Unaudited) PROPANC BIOPHARMA, INC. AND SUBSIDIARYCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited) PROPANC BIOPHARMA, INC. AND SUBSIDIARYNOTES TO CO